Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Gets Second Chance On Dual PPAR: Will Develop Bristol’s Muraglitazar

Executive Summary

Merck's co-development agreement for Bristol Myers-Squibb's Phase III muraglitazar gives the company a second chance to market a dual PPAR agonist

You may also be interested in...



Bristol Outsourcing Of Cefzil, Tequin To Ventiv May Be New Model For CSOs

Bristol Myers-Squibb's sales agreement with Ventiv for the promotion of the antibiotics Cefzil and Tequin may be a new model for using contract sales organizations in an environment of downsizing

Merck To Sign 50 Business Development Deals In 2005

Merck's goal is to sign about 50 business development deals in 2005, the same level as 2004, the company said

Bristol Outsourcing Of Cefzil, Tequin To Ventiv May Be New Model For CSOs

Bristol Myers-Squibb's sales agreement with Ventiv for the promotion of the antibiotics Cefzil and Tequin may be a new model for using contract sales organizations in an environment of downsizing

Related Content

UsernamePublicRestriction

Register

PS043877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel